leadf
logo-loader
viewPredictmedix Inc.

Predictmedix poised to take technology to the UK as it wins sales contract with NHS supplier

The AI-focused healthcare group also said it had filed two patent applications with the US patent and trademark office

Business handshake
The Taurus deal is for 12 months, beginning on July 6, with an option for renewal if a certain number of clients come onboard.

Predictmedix (CSE:PMED) (OTCQB:PMEDF) has struck a sales contract for its coronavirus (COVID-19) screening technology with UK-based distributor Taurus Medical Solutions, which also supplies the country's national health service (NHS).

Also in the statement, the AI-focused healthcare group said it had filed two patent applications with the US patent and trademark office for its telehealth/telemedicine and remote patient monitoring platform.

WATCH: PredictMedix files two U.S. patents for technology while seeing big growth potential in Europe 

The Taurus deal is for 12 months, beginning on July 6, with an option for renewal if a certain number of clients come onboard.

"We are excited to be working with Taurus Medical Solutions as it marks a new beginning for us with our global expansion efforts," said Dr. Rahul Kushwah, chief operating officer (COO) of Predictmedix.

"Their large and diverse client base in the UK along with their relationship with the NHS offers us a great opportunity to roll out our technologies in the healthcare sector in the UK."

Dr Arun Chauhan, a UK based expert in digital health, added: "In this crucial phase of COVID-19 pandemic when most of the countries are opening up and the communities are restoring their movement Predictmedix screening solution for COVID-19 symptom screening brings a ray of hope for communities."

The two US patents cover the firm's technology on adapting a treatment regimen and managing a rewards program for patients.

The technology developed by Predictmedix (patent pending) uses artificial intelligence in automatically recommending and adapting to a treatment regimen, the firm said in the statement.

Meanwhile, amid a large scale outbreak of various infectious, non-infectious, heredity and other lifestyle diseases, it has become increasingly important nowadays that patients follow treatment protocols.

"The technology developed by Predictmedix (patent pending) provides a novel method and system of management of a reward program for a patient treatment program," said Predictmedix.

"The two patents are the key to further expand the offering of our telehealth/telemedicine, remote patient monitoring platform and these patents clearly help us distinguish ourselves in the telehealth space by providing cutting artificial intelligence based tools which go beyond the traditional scope of telemedicine", added Dr Kushwah.

Contact the author at [email protected]

Quick facts: Predictmedix Inc.

Price: 0.32 CAD

CSE:PMED
Market: CSE
Market Cap: $32.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Predictmedix Inc. named herein, including the promotion by the Company of Predictmedix Inc. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

PredictMedix looking to leverage platform to become industry leader in 3 AI...

PredictMedix (CSE: PMED-OTCQB: PMEDF) CEO Dr. Rahul Kushwah joined Steve Darling from Proactive Vancouver to provide an update on the many milestones the company has hit so far this year. Dr. Kushwah telling Proactive about each of their verticals and also commenting on the many contracts...

4 weeks ago

2 min read